David Charles Lubner's most recent trade in Arcellx Inc was a trade of 6,000 Common Stock done at an average price of $75 . Disclosure was reported to the exchange on Jan. 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcellx Inc | David Charles Lubner | Director | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 20 Jan 2026 | 6,000 | 21,659 | - | 75 | 450,000 | Common Stock |
| Arcellx Inc | David Charles Lubner | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2026 | 6,000 | 59,405 | - | - | Stock Option (right to buy) | |
| Arcellx Inc | David Charles Lubner | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.28 per share. | 20 Jan 2026 | 6,000 | 27,659 | - | 6.3 | 37,680 | Common Stock |
| CARGO Therapeutics Inc | David Charles Lubner | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Aug 2025 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| CARGO Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 35,000 | 35,000 | - | - | Stock option (right to buy) | |
| Arcellx Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,174 | 9,174 | - | - | Stock Option (right to buy) | |
| Vor Biopharma Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| CARGO Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 23,742 | 23,742 | - | - | Stock Option (Right to Buy) | |
| Arcellx Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2024 | 8,011 | 8,011 | - | - | Stock Option (right to buy) | |
| Vor Biopharma Inc | David Charles Lubner | Director | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | ||
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 25,133 | 25,133 | - | - | Stock option (right to buy) | |
| POINT Biopharma Global Inc | David Charles Lubner | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 44,749 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Lubner David Charles | Director | 26 Dec 2023 | 35,400 | 3,600 | - | - | Common Stock | ||
| POINT Biopharma Global Inc | David Charles Lubner | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 25,614 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | David Lubner Charles | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Lubner David Charles | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 3,600 | 0 | - | - | Common Stock | |
| Arcellx Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 11,459 | 11,459 | - | - | Stock Option (right to buy) | |
| POINT Biopharma Global Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 44,749 | 44,749 | - | - | Stock Option (Right to Buy) | |
| Vor Biopharma Inc | David Charles Lubner | Director | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | ||
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 24,900 | 24,900 | - | - | Stock Option (right to buy) | |
| POINT Biopharma Global Inc | David Charles Lubner | Director | Purchase of securities on an exchange or from another person at price $ 6.85 per share. | 23 Nov 2022 | 3,600 | 3,600 | - | 6.9 | 24,660 | Common Stock |
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 7,222 | 7,222 | - | - | Stock Option (right to buy) | |
| Vor Biopharma Inc | David Charles Lubner | Director | 14 Jun 2022 | 16,911 | 16,911 | - | - | Stock Option (right to buy) | ||
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 19,596 | 19,596 | - | - | Stock Option (right to buy) | |
| POINT Biopharma Global Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 25,614 | 25,614 | - | - | Stock Option (Right to Buy) | |
| Arcellx Inc | David Charles Lubner | Director | 08 Feb 2022 | 21,659 | 0 | - | - | Series C Preferred Stock | ||
| Arcellx Inc | David Charles Lubner | Director | 08 Feb 2022 | 21,659 | 21,659 | - | 0 | Common Stock | ||
| Arcellx Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 61,538 | 61,538 | - | - | Stock Option (right to buy) | |
| Disc Medicine Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2021 | 17,245 | 17,245 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 19,596 | 19,596 | - | - | Stock Option (right to buy) | |
| Disc Medicine Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 58,855 | 58,855 | - | - | Stock Option (Right to Buy) | |
| Disc Medicine Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Vor Biopharma Inc | David Charles Lubner | Director | 05 Feb 2021 | 16,900 | 16,900 | - | - | Stock Option (right to buy) |